Trials / Completed
CompletedNCT01479530
Azilect® (Rasagiline) in Levodopa-treated Parkinson's Patients With Motor Fluctuations in China
Randomised, Double-blind, Parallel-group, Placebo-controlled, Fixed-dose Study of [Azilect®] Rasagiline in Levodopa-treated Parkinson's Patients With Motor Fluctuations in China
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 321 (actual)
- Sponsor
- H. Lundbeck A/S · Industry
- Sex
- All
- Age
- 30 Years
- Healthy volunteers
- Not accepted
Summary
The rationale for conducting this study is to evaluate the efficacy, tolerability, and safety of rasagiline compared to placebo in levodopa-treated Parkinson's Disease (PD) Chinese patients with motor fluctuations. Azilect® (Rasagiline) is indicated for the treatment of idiopathic PD as monotherapy (without levodopa) or as adjunct therapy (with levodopa) in patients with end of dose fluctuations.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Placebo | Once daily; tablet; orally; 16 weeks |
| DRUG | Azilect® | 1 mg daily; tablet; orally; 16 weeks |
Timeline
- Start date
- 2011-12-01
- Primary completion
- 2013-06-01
- Completion
- 2013-06-01
- First posted
- 2011-11-24
- Last updated
- 2018-09-10
- Results posted
- 2014-06-26
Locations
18 sites across 1 country: China
Source: ClinicalTrials.gov record NCT01479530. Inclusion in this directory is not an endorsement.